Diabetes drug could help fight brain cancer

NCT ID NCT07003542

Recruiting now Disease control Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether sitagliptin, a diabetes drug, can improve the immune system's ability to attack glioblastoma, an aggressive brain tumor. The study will enroll 48 adults with grade 4 glioma who are scheduled for surgery. Some participants will receive sitagliptin before surgery, and researchers will compare immune cell levels in the tumor to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sitagliptin
What this could lead to: If it works, this could point toward a new way to treat glioblastoma by helping the immune system fight the tumor.
What could go wrong: This is an early phase 2 trial with only 48 people, so results may not apply widely. Sitagliptin is not yet proven for this cancer, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR GLIOBLASTOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
RECRUITING

Cleveland, Ohio, 44195, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.